Patients with peripheral artery disease undergoing percutaneous peripheral interventions are at increased risk for complications without adequate anticoagulation.
Percutaneous peripheral interventions (PPI) are often complex procedures performed on high-risk patients with a significant thrombus burden. Although there is no approved anticoagulant for use in PPI, heparin is commonly used but is associated with several limitations. The APPROVE data provide a foundation for further study of bivalirudin in the setting of PPI.